Department of Nephrology, Qilu Hospital of Shandong University, No. 107 Wenhua West Road, 250000, Jinan, Shandong, PR China.
BMC Nephrol. 2023 Jul 18;24(1):214. doi: 10.1186/s12882-023-03079-4.
Rituximab, a chimeric anti-CD20 monoclonal antibody, is an effective treatment for nephrotic syndrome. Hypokalemia is a rare adverse reaction among patients treated with rituximab although there have been extensive reports of acute and chronic adverse events with the administration of rituximab. We herein report two cases of symptomatic hypokalemia after intravenous rituximab administration in our center, to help health professionals consider the possibility of acute hypokalemia after rituximab administration, monitor potassium timely and develop an appropriate treatment plan.
利妥昔单抗，一种嵌合抗 CD20 单克隆抗体，是治疗肾病综合征的有效药物。尽管利妥昔单抗的使用有广泛的急性和慢性不良反应的报道，但低钾血症是接受利妥昔单抗治疗的患者中罕见的不良反应。在此，我们报告了两例在我们中心接受静脉注射利妥昔单抗后出现症状性低钾血症的病例，以帮助医务人员在利妥昔单抗治疗后考虑急性低钾血症的可能性，及时监测钾水平并制定适当的治疗方案。
